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Abstract
Background: Alzheimer’s disease (AD) is characterized by progressive cognitive decline and memory loss.
Environmental factors and gene-environment interactions (GXE) may increase AD risk, accelerate cognitive decline,
and impair learning and memory. However, there is currently little direct evidence supporting this hypothesis.
Methods: In this study, we assessed for a GXE between lead and ApoE4 on cognitive behavior using
transgenic knock-in (KI) mice that express the human Apolipoprotein E4 allele (ApoE4-KI) or Apolipoprotein E3
allele (ApoE3-KI). We exposed 8-week-old male and female ApoE3-KI and ApoE4-KI mice to 0.2% lead acetate
via drinking water for 12 weeks and assessed for cognitive behavior deficits during and after the lead
exposure. In addition, we exposed a second (cellular) cohort of animals to lead and assessed for changes in
adult hippocampal neurogenesis as a potential underlying mechanism for lead-induced learning and memory
deficits.
Results: In the behavior cohort, we found that lead reduced contextual fear memory in all animals; however,
this decrease was greatest and statistically significant only in lead-treated ApoE4-KI females. Similarly, only
lead-treated ApoE4-KI females exhibited a significant decrease in spontaneous alternation in the T-maze.
Furthermore, all lead-treated animals developed persistent spatial working memory deficits in the novel object
location test, and this deficit manifested earlier in ApoE4-KI mice, with female ApoE4-KI mice exhibiting the
earliest deficit onset. In the cellular cohort, we observed that the maturation, differentiation, and dendritic
development of adult-born neurons in the hippocampus was selectively impaired in lead-treated female
ApoE4-KI mice.
Conclusions: These data suggest that GXE between ApoE4 and lead exposure may contribute to cognitive
impairment and that impaired adult hippocampal neurogenesis may contribute to these deficits in cognitive
behavior. Together, these data suggest a role for GXE and sex differences in AD risk.
Keywords: Lead, Apolipoprotein E, Cognitive behavior, Adult hippocampal neurogenesis, Learning and
memory
* Correspondence: zxia@u.washington.edu
1Toxicology Program, Department of Environmental and Occupational
Health Sciences, University of Washington, Box 357234, Seattle, WA 98195,
USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Engstrom et al. Molecular Neurodegeneration  (2017) 12:14 
DOI 10.1186/s13024-017-0155-2
Background
Alzheimer’s disease (AD) is the most common age-related
neurodegenerative disorder [1]. Autosomal dominant
mutations account for less than 5% of all Alzheimer’s
cases [2], thus, most AD cases are likely due to a combin-
ation of environmental and genetic risk factors [3–5]. A
gene-environment interaction (GXE) between genetic risk
factors and environmental exposures may perturb
hippocampus-dependent learning and memory, accelerate
cognitive decline, and contribute to neurodegenerative
diseases, including AD. However, there is a paucity of
information supporting this GXE hypothesis.
Apolipoprotein E4 allele (ApoE4) is the strongest
genetic risk factor for late-onset AD [6]; it increases the
frequency and decreases the age at onset of AD in a
gene dose-dependent manner [6]. ApoE4 carriers also
have a worse prognosis following traumatic brain injury,
a higher prevalence of mild cognitive impairment, and
accelerated cognitive decline [7–11].
ApoE4 impairs hippocampus-dependent learning and
memory in an age- and sex-dependent manner in trans-
genic knock-in (KI) mouse models [12–14]. In contrast to
aging ApoE3-KI mice or male ApoE4-KI mice, female
transgenic ApoE4-KI mice exhibit spatial learning and
memory deficits starting at 16 months of age [12, 14].
Interestingly, female human ApoE4 carriers have an in-
creased risk of AD compared to males, and female ApoE4
carriers with mild cognitive impairment experience
greater hippocampal volume loss and reduced memory
performance [15, 16]. Due to the negative effects of
ApoE4 on cognition, ApoE4 carriers, particularly female
carriers, may be more susceptible to toxicant-induced
cognitive impairment compared to ApoE4 non-carriers.
Lead is a ubiquitous environmental contaminant and a
significant public health concern in the U.S. and globally
[17–19]. This is exemplified by the recent water crisis in
Flint, Michigan, where the water supply was contaminated
with lead due to lead leaching from old water pipes. The
fact that many U.S. cities still have lead service pipes for
water distribution underscores the continuing risk of lead
exposure in the U.S. [20].
Both animal and epidemiological studies have reported
an association between lead exposure and accelerated
cognitive decline and/or AD-associated neuropathology in
adults [21–25]. Interestingly, among workers occupation-
ally exposed to lead, those with at least one ApoE4 allele
experienced accelerated cognitive decline relative to
ApoE4 non-carriers [26]. This epidemiological finding
suggests that an interaction between lead and ApoE4 may
accelerate cognitive decline. However, an experimental
model is necessary in order to directly assess for a GXE
between ApoE4 and lead regarding cognitive impairment.
In this study, we used homozygous male and female
ApoE3-KI and ApoE4-KI mice as an experimental model
in order to assess the effect of lead exposure and ApoE4
on cognitive behavior and to examine any potential
sex differences in susceptibility. We used deficits in
hippocampus-dependent learning and memory as a
measure of cognitive decline and AD-related memory
impairment because the hippocampus is one of the
earliest brain regions affected in AD patients and def-
icits in hippocampus-dependent spatial learning and
memory may develop prior to the onset of a clinical
diagnosis [27–29].
Interestingly, perturbation of adult hippocampal neuro-
genesis may cause cognitive behavior deficits, accelerate
cognitive decline, and increase AD risk [30]. During adult
hippocampal neurogenesis, adult neural precursor cells in
the dentate gyrus (DG) of the hippocampus continuously
generate adult-born neurons [31] which contribute to
hippocampus-dependent learning and memory [32–37].
Various factors have been shown to modulate adult neuro-
genesis [31, 33, 34, 37, 38], however, little is known about
whether toxicants or GXE may impair adult hippocampal
neurogenesis. ApoE is expressed in adult neural precursor
cells in the DG [6, 31, 39], and in vivo studies using
ApoE4-KI mice found that ApoE4 alters adult-born
neuron survival and maturation in an age- and sex-
dependent fashion [12–14, 40]. Furthermore, we previ-
ously reported that lead can impair the proliferation,
survival, and differentiation of adult neural precursor cells
from the DG of the hippocampus in vitro [41]. No study
to date has assessed the effect of adult-only lead exposure
on adult hippocampal neurogenesis and cognitive behav-
ior. Thus, we also investigated whether impaired adult
hippocampal neurogenesis may contribute to this GXE
between ApoE4 and lead exposure regarding cognitive
impairment.
Methods
Mice
Humanized Apolipoprotein E3 and E4 knock-in (ApoE3-
KI and ApoE4-KI) mice were generated as previously
described [42] and provided by Dr. Nobuyo Maeda at
the University of North Carolina, Chapel Hill. The
human E3 or E4 allele in the ApoE3-KI or ApoE4-KI
mice is expressed at physiological levels under control of
the endogenous mouse ApoE promoter [13]. ApoE3-KI
and ApoE4-KI animals were maintained as homozygous
lines and all animals were housed in standard conditions
(12 h light/dark cycle) with food and water provided ad
libitum.
Reagents
Animal drinking water with 0.2% lead (II) acetate (Cat.
316512, Sigma-Aldrich, St. Louis, MO) was prepared
from a stock lead acetate solution and replaced weekly.
The preparation, use, and disposal of hazardous agents
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was carried out according to the Environmental Health
and Safety Office at the University of Washington.
Lead exposure
Male and female ApoE3-KI and ApoE4-KI animals were
weaned at 28 days and littermates of the same sex were
randomly mixed into groups of 3–5 animals per cage. At
8 weeks of age, the mice were either switched to drinking
water with 0.2% lead acetate (lead-treated) or kept on
normal animal drinking water (control). Body weight was
recorded every 1–2 weeks throughout the exposure. Water
consumption was monitored for the first week of the ex-
posure period. Lead-treated animals were exposed to lead
drinking water for 12 weeks, at which point all the animals
were switched to normal drinking water for the remaining
duration of the study for the behavior cohort. We used
separate cohorts of animals, one for behavior and one for
cellular studies, to assess cognitive behavior and adult
hippocampal neurogenesis, respectively. The behavior
cohorts had n = 8–13 animals per genotype/treatment/sex
and the cellular cohorts had n = 6–10 animals per geno-
type/treatment/sex.
Open field test
The open field test was conducted before and after the
lead exposure to assess for the development of any lead-
induced locomotor deficits or anxiety. Briefly, each animal
was placed into a TruScan Photo Beam Tracking arena
(Colbourn Instruments, Whitehall, PA) with Plexiglas
walls (10″ X 10″ X 16″) and their movement was moni-
tored with two sets of infrared breams. The animal was
allowed to freely explore the arena for 20 min and the data
was collected by TruScan 2.0 software (Colbourn
Instruments).
Elevated plus maze
We conducted the elevated plus maze test in order to
assess the effect of lead exposure on anxiety. The maze
(26″ x 26″ x 15.25″; San Diego Instruments, San Diego,
CA) consisted of four plastic arms with 7″ walls (two
enclosed and two open), and it was placed in the center
of the behavior room. Each animal was placed into the
center of the maze facing an open arm and allowed to
freely explore the maze for 5 min. The open and closed
arm ends were defined as the distal 1/3 of the arms.
ANYmaze software (San Diego Instruments) was used to
collect data on the animal’s movement during the test.
Novel object location test
In order to assess hippocampus-dependent, short-term
spatial working memory, we used the 1 h novel object
location (NOL) test. This test was performed as previ-
ously described with a few modifications [34]. Briefly,
each animal was placed into an open field arena
(Colbourn Instruments) with two identical objects in
two different locations. During training, the animal was
allowed to freely explore the two objects for 5 min and
then returned to its home cage. After 1 h, the animal
was returned to the arena with the same two objects;
one object remained in its original location and one
object had been moved to a novel location. The time the
animal spent actively investigating each object during
the training and testing was quantified. Each training
and testing session was recorded and scored offline by
an experimenter blinded to the animal’s genotype and
treatment. We calculated the discrimination index by
dividing the difference in exploration time between the
novel (C) and familiar (A) locations by the total explor-
ation time.
Cued-contextual fear-conditioning
Contextual fear conditioning is another form of
hippocampus-dependent learning and memory [33, 37, 43].
We tested 5–6-month-old animals and used a weak foot
shock conditioning paradigm (3 x 0.3 mA, 2 s shocks with
2 min inter-trial intervals) as previously described [33]. For
conditioning, the mouse was placed into the foot shock
context (10″ x 10″ x 16″ arena with grid shock floor (Col-
bourn Instruments) and star-shaped wallpaper) and allowed
to freely explore the arena for 2 min before the presentation
of a 90 dB, 30 s tone (conditioned stimulus, CS). During
the last 2 s of the tone presentation, a 0.3 mA foot shock
(unconditioned stimulus, US) was delivered via the grid
shock floor. This cycle was repeated two more times for a
total of three cycles before the animal was returned to its
home cage. The CS and US were automated and delivered
by TruScan software (Colbourn Instruments). The context-
ual fear memory test was conducted 24 h after condition-
ing. The mouse was placed back into the foot shock
context for 2 min in the absence of any foot shock. For the
cued test (performed 2 h after context test), the animal was
placed into a different context (new room; hexagonal Plexi-
glas arena; cartoon wallpaper) and allowed to freely explore
for 2 min followed by the presentation of the CS for 2 min.
For the novel context test (performed 2 h after the cued
test), the mouse was placed into a novel context (new
room; rat cage; striped wallpaper) and allowed to freely
explore without any CS or US presentation. In all three
tests, persistent freezing behavior (four paws on the ground,
no head or body movement besides breathing) was
recorded manually every 5 s during the 2 min scoring
periods by an experimenter blinded to animal genotype and
treatment.
T-maze continuous alternation task
We assessed spontaneous alternation in 12–13- month-
old animals using a continuous alternation T-maze
protocol with slight modifications [44]. Briefly, the black,
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plastic T-maze had two goal arms and a start arm (12.2″
x 4.5″ x 8.26″), and was placed on a platform (22.5″) in
the center of a room. The test consisted of a first-forced
trial followed by 14 free-choice trials. For the first-forced
trial, one of the goal arms was (randomly) blocked with
a plastic guillotine door. The animal was sequestered in
the distal one-third of the start arm for 5 s before the
guillotine door was raised and the animal was allowed to
enter the unblocked goal arm. Once the animal returned
to the start arm, it was sequestered in the start arm for
5 s before the start of the 14 free-choice trials. For each
free-choice trial, the mouse was allowed to enter either
of the unblocked goal arms; once it entered a goal arm,
the other goal arm was blocked with a guillotine door.
The animal eventually returned to the start arm and was
sequestered for 5 s while all of the goal arms were
unblocked. This was repeated for a total of 14 free-
choice trials. The alternation percentage was calculated
by dividing the number of times the animal entered
alternating arms by 14 (free-choice trials). We defined
arm entry as the animal’s tail tip entering the arm and
defined repetitive arm entries as an animal re-entering
the same arm three times in a row (e.g., 5 sequential
entries into the same arm is 3 repetitive entries). An
experimenter blinded to animal genotype and treatment
scored each test.
Brain and blood lead analysis
We collected blood and brain tissue for lead analysis at
sacrifice after the cessation of the lead exposure from a
subset of the mice in the cellular cohort (20 weeks old; n
= 3–5 per genotype/sex/treatment). The Environmental
Health Laboratory at the University of Washington mea-
sured blood lead levels using inductively coupled plasma
mass spectrometry (ICP-MS; Agilent 7500ce, Agilent
Technologies, Santa Clara, CA). The spatial distribution
and semi-quantitative measurement of lead and zinc levels
(ppm) in 30 μm brain hemisphere sections from 20-week-
old ApoE4-KI control or lead-treated females was deter-
mined by laser ablation ICP-MS (LA-ICP-MS) using an
NWR213 laser ablation system (ESI, Portland, OR) con-
nected to an Agilent 7500ce ICP-MS (Agilent Technolo-
gies, Santa Clara, CA). Quantification was achieved using
spiked protein matrix as external standards.
TUNEL staining
TUNEL staining was performed using the Trevigen
TACS 2 TdT-fluor In situ Apoptosis Detection Kit (Cat.
4812-30-K, Sigma-Aldrich, St. Louis, MO) on 30 μm
fresh frozen coronal brain sections according to the
manufacturer’s instructions. The cells were perme-
abilized using Trevigen’s CytoninTM permeabilization
buffer and an experimental positive control was included
(treated with TACS-NucleaseTM).
Quantification of dentate gyrus volume
The volume of the dentate gyrus was quantified using
coronal images (20X magnification) from 15-month-old
female ApoE3-KI and ApoE4-KI mice from the behavior
cohorts as previously described [45].
BrdU administration
5-bromo-2′-deoxyuridine (BrdU) was from Sigma (Cat.
B9285, Sigma-Aldrich, St. Louis, MO) and stored as a
20 mg/ml stock in saline with 0.007% NaOH at -20 °C.
After 9 weeks of lead exposure, the mice in one of the
cellular cohorts were dosed with 100 mg/kg BrdU by
intraperitoneal injection 5 times in 1 day (every 2 h) and
sacrificed 3 weeks later (at the end of the 12 week lead
exposure) in order to assess the maturation of BrdU-
labeled adult-born cells. A second cellular cohort was
dosed with BrdU 1 X 100 mg/kg 2 h prior to sacrifice (at
the end of the 12 week lead exposure period) in order to
assess for proliferative BrdU-labeled cells.
Immunohistochemistry
The primary antibodies and dilutions used in immunohis-
tochemistry were: rat monoclonal anti-BrdU (1:500, Bio-
Rad Laboratories AbD Serotec, Raleigh, NC), mouse mono-
clonal anti-NeuN (1:1000, Millipore, Billerica, MA), mouse
monoclonal anti-GAD67 (1:2000, Millipore, Billerica, MA),
and donkey polyclonal anti-DCX (1:200, Santa Cruz Bio-
technology, Dallas, TX), Goat anti-rat, goat anti-mouse,
and donkey anti-rat Alexa Fluor-conjugated secondary anti-
bodies as well as Hoechst 33342 (2.5 μg/ml) were from
Invitrogen (Carlsbad, CA). All of the primary and second-
ary antibodies were diluted into the appropriate blocking
buffer (10% donkey or goat serum and 1% BSA).
Mice were anesthetized with ketamine/xylazine and then
euthanized by decapitation. One brain hemisphere was
freshly frozen for brain lead analysis or other biochemical
analysis, while the other hemisphere was post-fixed in 10%
neutral-buffered formalin for 3–4 days followed by 30% (w/
v) sucrose in phosphate-buffered saline (PBS, pH 7.4) at 4 °
C for 3–4 days until saturated. Each post-fixed hemisphere
was then stored in cryoprotectant media (30% glycerol; 30%
ethylene glycol; 40% PBS) at -80 °C until sectioning. Coronal
brain sections (30 μm thick) were used for immunohisto-
chemistry (IHC) using the free-floating antibody staining
method as previously described [38].
Quantification and imaging of immunostained cells
Immunostained cells were quantified as previously de-
scribed [34, 38]. Every eighth serial section (30 μm) was
immunostained for each IHC marker (or combination of
markers). An experimenter blinded to treatment and
genotype quantified marker+ cells in the subgranular
zone and granule cell layer of the DG. This number was
multiplied by 8 in order to estimate the total number of
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marker+ cells per DG. Marker colocalization (double-
positive cell) was defined as overlapping fluorescent
signals in a single cell using a Z-series stack. All the
marker+ cells from at least 9 coronal sections per mouse
(n = 3–5 mice per genotype/sex/treatment) were quanti-
fied for each immuno marker or marker combination.
All images were captured with an Olympus Fluoview-
1000 laser scanning confocal microscope with the
following lenses: numerical aperture (NA) 0.75 10X, NA
0.75 20X, NA1.3 40X (oil), or NA 1.35 60X (oil). Optical
Z-sections (1 μm thick) were collected and processed
using ImageJ software (NIH, Bethesda, MD). Images
were uniformly adjusted for color, brightness, and
contrast with Adobe Photoshop CS4 (Adobe Systems
Inc., San Jose, CA).
Quantification of dendritic morphology
The dendritic morphology of DCX+ cells in control and
lead-treated ApoE3-KI and ApoE4-KI mice (at least 13
individual neurons per genotype/sex/treatment) was
assessed by Sholl analysis as previously described [34].
Histology
Kidney and liver sections from control and lead-treated
ApoE3-KI and ApoE4-KI males and females (n = 3–4 per
genotype/treatment) were fixed in 10% neutral buffered for-
malin, paraffin embedded, cut into 4- to 5-μm sections,
routinely stained with hematoxylin and eosin (H&E), and
evaluated by a board-certified veterinary pathologist. Slides
were coded to remove information regarding genotype and
treatment. Kidneys were scored semi-quantitatively using a
0–4 scale, in which “0” was normal; “1” indicated minimal
expansion of the glomerular mesangial matrix and minimal
multifocal tubular protein; “2” indicated mild changes of
the glomerulus with mild interstitial fibrosis, interstitial
nephritis, and tubular protein; “3” indicated moderate
multifocal to coalescing changes characterized by more
pronounced glomerular, tubular and interstitial changes;
and “4” indicated end stage disease with obsolescent glom-
eruli and severe multifocal to coalescing interstitial neph-
ritis and fibrosis with or without dilation of the renal pelvis
(hydronephrosis). Intranuclear inclusion bodies within the
proximal renal tubules were noted when present. Livers
were assessed using modified criteria from a previous study
[46] and scored semi-quantitatively for changes including
necrotic foci, cytoplasmic vacuolation, and mononuclear
cell infiltration on a 0–4 system in which “0” was normal;
“1” indicated minimal changes; “2” indicated mild changes;
“3” indicated moderate changes; and “4” indicated severe
changes. Images of representative lesions were acquired
using NIS-Elements BR 3.2 64-bit and plated in Adobe
Photoshop Elements. Image brightness and contrast was
adjusted using Auto Smart Fix and Auto White Balance
manipulations applied to the entire image.
Statistical analysis
Statistical analyses were conducted using GraphPad Prism
software (version 6.0 h for Mac, GraphPad Software Inc.,
San Diego, CA, USA) and Stata (version 12.0 for Mac,
StataCorp LP, College Station, TX, USA). Two-way analysis
of variance (ANOVA) with the Holm-Sidak post-test (α =
0.05) was used to analyze the open field, elevated plus maze,
contextual fear, and T-maze data in order to account for the
main effect of genotype (ApoE3-KI vs. ApoE4-KI), treatment
(control vs. lead), or time. Two-tailed t-test (α= 0.05) was
used for within-genotype comparisons for the NOL data.
Multilevel mixed-effects linear regression (α= 0.05) was
used for longitudinal analysis of within-genotype NOL dis-
crimination index data. Two-way analysis of variance
(ANOVA) with Fisher’s LSD post-test (α = 0.05) was used to
analyze all of the cellular data. All data represent mean ±
SEM, n.s. not significant; * p < 0.05; ** p < 0.01; *** p < 0.001.
Results
ApoE3-KI and ApoE4-KI mice do not exhibit weight loss,
locomotor deficits, or anxiety following lead exposure
We exposed 8-week-old male and female ApoE3-KI and
ApoE4-KI mice to 0.2% lead acetate (lead-treated) or
normal drinking water (control) for 12 weeks to model
sub-chronic environmental and occupational exposure
through ingestion (Fig. 1). We used 0.2% lead acetate in
our study because this concentration has been used
extensively in the literature to study lead neurotoxicity
in mice [47–52]. We recorded body weight every 1–2
weeks during the lead exposure period and did not ob-
serve any weight loss in any of the lead-exposed animals
at any time during lead exposure (Fig. 1b). Lead-treated
ApoE3-KI mice were slightly heavier than their controls
at several time points, but this weight gain was not asso-
ciated with any locomotor deficits. There was no signifi-
cant difference in body weight between control and
lead-treated ApoE4-KI mice.
We conducted the open field test for all of the animals
in the behavior cohort before and after the 12-week lead
exposure in order to assess locomotor activity and anxiety.
The pre-exposure test was performed to exclude any in-
trinsic differences between the control and lead-treated
cohorts that could complicate data interpretation. Al-
though there were some small differences in locomotor
activity between the two genotypes, with ApoE4-KI mice
exhibiting slightly higher baseline activity than ApoE3-KI
mice, there were no significant differences in open field
activity between control and lead-treated cohorts prior to
the lead exposure of either genotype (data not shown).
After lead exposure, the lead-treated females, both
ApoE3-KI and ApoE4-KI, traveled further, spent more
time moving, and moved slightly faster than their re-
spective controls (Fig. 2). There was no significant effect
of lead on locomotor activity in male mice. It is
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important to note that there were no significant differ-
ences in locomotor activity between lead-treated ApoE3-
KI and ApoE4-KI mice of either sex.
We also used the open field test to determine if lead
treatment caused anxiety, measured as more time or dis-
tance in the margin, less time or distance in the center, or
reduced center entries. Lead treatment did not change
these parameters in males (Fig. 3a-f). Lead-treated
ApoE3-KI females traveled a greater distance in the center
of the open field and made more center entries compared
to ApoE3-KI control females (Fig. 3d-f). Notably, there
were no significant differences in center distance traveled
and center entry between lead-treated ApoE3-KI and
ApoE4-KI females.
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a Experimental design and timeline for the behavior cohort. b Body weight was measured every 1–2 weeks during the lead exposure
window. The lead-treated mice did not exhibit any weight loss relative to controls of the same sex and genotype. ApoE3-KI mice exposed to lead
weighed slightly but significantly more at several time points than control mice during the lead exposure. Data are mean ± SEM with n = 8–13 per
genotype/sex/treatment. Two-way ANOVA, significant main effect of treatment: n.s., not significant; * p < 0.05; ** p < 0.01
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Fig. 2 Lead-treated ApoE3-KI and ApoE4-KI male and female mice do not exhibit locomotor deficits in the open field test compared to controls.
Mice were exposed to lead as previously described and the open field test was conducted after the cessation of the lead exposure. There was a
significant main effect of lead treatment in female animals on floor plane distance, moving time, and average speed (Two-way ANOVA: floor
plane distance, F(1,31) = 22.85, p < 0.0001; moving time, F(1,31) = 20.47, p < 0.0001; average speed, F(1,31) = 20.49, p < 0.0001). Post-hoc analyses
found that lead-treated ApoE3-KI and/or ApoE4-KI females traveled a (a) greater distance, (b) spent the same or more time moving, and (c)
traveled slightly faster than controls. There were no significant differences between lead and control ApoE3-KI and ApoE4-KI males or between
lead-treated ApoE3-KI and ApoE4-KI mice (males or females) in any of the locomotor endpoints. Data are mean ± SEM with n = 8–13 per
genotype/sex/treatment. Two-way ANOVA with Holm-Sidak post-hoc tests: n.s., not significant; * p < 0.05; *** p < 0.001
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We also conducted the elevated plus maze test to assess
anxiety after the cessation of the lead exposure (Fig. 3g-j).
The elevated plus maze is commonly used to assess the
anxiogenic and anxiolytic effects of toxicological and
pharmacological agents. It relies on a mouse’s natural
avoidance of heights and open spaces and it’s preference
for dark, sheltered spaces [53]. There was no significant
effect of genotype or lead exposure on the percent of total
time males or females spent or the total distance they trav-
eled in the open arms by two-way ANOVA (Fig. 3g, h). In
addition, there was no significant effect of genotype or
treatment on the number of open arm entries or open
arm end entries among males or females (Fig. 3i, j).
Thus, subchronic exposure of 8-week-old mice to 0.2%
lead acetate did not decrease locomotor activity or cause
anxiety in ApoE3-KI or ApoE4-KI mice. Although lead
exposure may result in a slight hyperactive phenotype in
ApoE3-KI and ApoE4-KI females and a slight anxiolytic
phenotype in ApoE3-KI females, there were no signifi-
cant differences between lead-treated ApoE3-KI and
ApoE4-KI mice of either sex.
ApoE4-KI females exposed to lead exhibit impaired
contextual fear memory
We also conducted a contextual fear-conditioning test (age
of mice: 5–6 months old) to characterize the effect of lead
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Fig. 3 Male and female ApoE3-KI and ApoE4-KI mice exposed to lead do not exhibit overt anxiety in the open field test or elevated plus maze. The
open field test was used to determine if lead treatment causes anxiety, measured as more time or distance in the margin, less time or distance in the
center, or reduced center entries. There was a significant main effect of lead treatment in female mice on center distance and center entries (Two-way
ANOVA: center distance, F(1,31) = 5.936, p = 0.0208; center entries, F(1,31) = 14.76, p = 0.0006). Post-hoc analyses found that there were no significant
differences between lead-treated ApoE3-KI and ApoE4-KI mice (males and females) on the (a) time or (b) distance traveled in the margins, the (c) time
or (d) distance traveled in the center, or the (e) number of center entries in the open field test. D, ApoE3-KI females treated with lead
traveled a slightly greater distance in the center and E, made more center entries than controls. There were no significant differences
between control and lead-treated ApoE4-KI females, ApoE3-KI males, or ApoE4-KI males in the open field test. f Representative open field
track plots from female control and lead-treated ApoE3-KI and ApoE4-KI mice. In the elevated plus maze, both male and female ApoE3-KI
and ApoE4-KI mice exposed to lead spent a (g) similar or greater amount of time and traveled a (h) similar or greater distance in the
open arms of the maze compared to controls. Lead-treated males and females did not exhibit reduced (i) open arm or (j) open arm end
entries compared to control animals. Data are mean ± SEM with n = 8–13 per genotype/treatment. Two-way ANOVA with Holm-Sidak
post-hoc tests: n.s., not significant; * p < 0.05; *** p < 0.001
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and ApoE4 on hippocampus-dependent learning and mem-
ory (Fig. 4a). We used a 0.3 mA x 3 foot shock paradigm
because we previously reported that this paradigm is sensi-
tive to changes in contextual fear memory and adult neuro-
genesis [33]. All mice showed minimal freezing behavior at
baseline before foot shock (Fig. 4b, c). We performed the
context test 24 h after fear-conditioning in order to assess
contextual fear memory. Interestingly, lead-treated ApoE4-
KI females had significantly reduced contextual fear mem-
ory compared to ApoE4-KI controls (Fig. 4b). Male ApoE4-
KI mice and both male and female ApoE3-KI mice exposed
to lead exhibited a statistically non-significant reduction in
freezing behavior upon lead treatment (Fig. 4b, c). Lead
treatment did not cause any statistically significant changes
in any animals in auditory-cued fear memory–a form of
amygdala-dependent, but hippocampus-independent mem-
ory–or in general freezing in a novel context. Furthermore,
lead treatment did not affect animals’ shock sensitivity (data
not shown). Thus, lead exposure impairs the formation
and/or retrieval of contextual fear memory in ApoE4-KI fe-
male mice.
ApoE4-KI females exhibit decreased spontaneous
alternation and increased repetitive arm entry in a T-
maze
We assessed spontaneous alternation using the T-maze
in 12–13-month-old animals. Rodents spontaneously al-
ternate the arms they enter in the T-maze, and this is
likely due to a combination of novelty-elicited explora-
tory behavior as well as spatial working memory [44,
54]. Interestingly, lead-treated ApoE4-KI females exhib-
ited a significant reduction in spontaneous alternation
(Fig. 5a) and had a significant increase in repetitive arm
entries compared to control ApoE4-KI females (Fig. 5b).
These behavior changes were specific to females and
were not observed in males. There were no significant
differences between control and lead-treated animals on
the ratio of left/right arm entries or mean session dur-
ation in either females or males (Fig. 5c, d). These data
suggest that there may be a GXE interaction between
lead and ApoE4 on spontaneous alternation and repeti-
tive entries. Furthermore, lead-treated female ApoE4-KI
mice are more sensitive than males. These differences
are not due to a bias in arm entries or significant
differences in task completion time.
ApoE3-KI and ApoE4-KI mice exposed to lead exhibit a
GXE interaction and sex differences in the onset of short-
term spatial memory deficits in the novel objection loca-
tion test (NOL)
We conducted a 1 h NOL test to assess hippocampus-
dependent spatial working memory before, during, and
after the lead exposure. Importantly, at each NOL time
point (baseline through 10 months post-lead), none of the
mice exhibited a preference for either object or location
during the training session, and there was no difference in
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revealed that this was only statistically significant between control and lead-treated ApoE4-KI females (Holm-Sidak post-hoc test: F(1,33) = 2.648, p=0.0245).
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the total exploration time between lead-treated and control
mice (data not shown).
Before lead exposure, all of the ApoE3-KI and ApoE4-KI
females and males spent significantly more time exploring
the object in the novel vs. familiar (C vs. A) location during
the test period, indicating that they remembered the
original object location (Fig. 6A). Seven weeks into the lead
exposure, all of the mice spent significantly more time
exploring the novel location except for lead-treated ApoE4-
KI females, which did not discriminate between the old vs.
new object locations (Fig. 6B). After 11 weeks of lead
exposure, both the lead-treated ApoE4-KI females and
males no longer discriminated between the familiar and
novel object locations while the lead-treated ApoE3-KI
mice continued to spend significantly more time exploring
the novel object location (Fig. 6C). Both the lead-treated
ApoE4-KI females and males continued to exhibit a deficit
in spatial working memory at 3, 6, and 10 months post-lead
exposure (Fig. 6D and data not shown). Lead-treated
ApoE3-KI mice still spent significantly more time exploring
the novel object location at 3, 6, and 10 months post-lead
exposure (Fig. 6D and data not shown). However, the differ-
ences in exploration time between the new vs. old object
locations became smaller over time among the ApoE3-KI
mice exposed to lead indicating poorer spatial memory.
We calculated the discrimination index for each NOL
test, and the discrimination indices at each time point are
summarized by genotype and sex in Fig. 7. There was an ef-
fect of lead exposure on the discrimination index in all
lead-exposed animals (Multiple mixed-effects linear
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Fig. 5 Lead impairs spontaneous alternation and increases repetitive arm entry in lead-treated ApoE4-KI females. Spontaneous alternation was
assessed using the T-maze at 12–13 months of age. a There was a significant main effect of genotype on spontaneous alternation in females
(Two-way ANOVA: genotype, F(1,32) = 7.666, p = 0.0093). Lead-treated ApoE4-KI female mice exhibited reduced spontaneous alternation
compared to female ApoE4-KI control mice (Holm-Sidak post-test: F(1,32) =2.356, p =0.0490). b There was a significant main effect of both
genotype and treatment on repetitive arm entries in females (Two-way ANOVA: genotype, F(1,32) = 5.915, p =0.0208; treatment, F(1,32) = 6.164, p
=0.0185). ApoE4-KI females exposed to lead exhibited significantly increased repetitive arm entries compared to control ApoE4-KI female mice
(Holm-Sidak post-test: F(1,32) = 2.584, p 0.0289). There was no significant difference in spontaneous alternation or arm re-entries in lead-treated
ApoE3-KI and ApoE4-KI male mice. c Female and male mice did not exhibit any arm preference. d There was a significant main effect of
genotype on mean session duration in both the females and males, with ApoE4-KI mice completing the alternation task slightly faster than
ApoE3-KI mice of the same sex (Two-way ANOVA: females, F(1,30) = 19.50, p = 0.0001; males F(1,41) =9.803, p = 0.0032). There was no significant
difference in mean session duration between control and lead-treated animals of the same genotype and sex. Data are mean ± SEM with
n = 8–13 per sex/genotype/treatment. n.s. not significant; * p < 0.05
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regression: ApoE3-KI females, p= 0.001; ApoE4-KI females,
p < 0.0001; ApoE3-KI males, p = 0.019; ApoE4-KI males, p
< 0.0001). During the lead exposure period, there was no
difference in the discrimination index between control and
lead-treated ApoE3-KI females (Fig. 7a). However, lead-
treated ApoE3-KI females had a significantly lower discrim-
ination index at 3 and 10 months post-lead exposure com-
pared to controls.
Interestingly, the lead-treated ApoE4-KI females had a
significantly lower discrimination index than control
ApoE4-KI females starting at 7 weeks into the lead ex-
posure, and this decrease persisted through 10 months
post-lead (Fig. 7b). Thus, lead-treated ApoE3-KI and
ApoE4-KI females exhibited persistent deficits in short-
term spatial memory, with ApoE4-KI females exhibiting
a significant decrease in the discrimination index start-
ing at 7 weeks into the lead exposure, much earlier than
lead-treated ApoE3-KI females at 3 months post-lead
exposure.
Lead-treated ApoE3-KI males had a significantly lower
discrimination index at 6 and 10 months post-lead com-
pared to controls (Fig. 7c), suggesting that spatial mem-
ory deficits can develop long after lead exposure. In
contrast, lead-treated ApoE4-KI males had a significantly
lower discrimination index than controls starting at
11 weeks into the lead exposure and this effect persisted
through 10 months post-lead exposure (Fig. 7d). Thus,
both ApoE3-KI and ApoE4-KI males exposed to lead ex-
hibited persistent deficits in short-term spatial memory,
but the lead-treated ApoE4-KI males showed these
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deficits much earlier (starting at 11 weeks into the lead
exposure vs. 6 months post-lead).
Together, data in Figs. 6 and 7 demonstrate that
ApoE4-KI mice exposed to lead developed impaired
spatial working memory much earlier than lead-treated
ApoE3-KI mice, in both males and females. When we
compare males and females of the same genotype, lead-
induced spatial memory deficits manifested earlier in fe-
males than in males for both the ApoE3-KI and ApoE4-
KI mice. These data suggest a GXE between lead expos-
ure and ApoE4 on cognitive impairment as well as sex
differences in the onset of cognitive deficits.
Lead-treated ApoE3-KI and ApoE4-KI mice do not exhibit
significant pathology in the DG and other tissues
In order to determine if lead exposure causes systemic
toxicity, we assessed for pathological changes in the liver
and kidney of 64-week-old (~15-month-old) male and
female ApoE3-KI and ApoE4-KI mice after various be-
havioral testing. There were no significant differences in
kidney or liver pathology scores between control and
lead-treated mice of either sex or genotype (Fig. 8a-d
and data not shown). Furthermore, there were no
changes in the volume of the DG of the hippocampus in
ApoE3-KI or ApoE4-KI females upon lead exposure
(Fig. 8e). In addition, we did not observe an increase in
TUNEL+ cells in the hippocampus or cortex of lead-
treated animals (Fig. 9). Thus, the lead exposure regimen
used in this study did not result in gross pathological
changes in the DG, kidney, or liver.
Adult lead exposure results in elevated blood lead levels
and lead deposition in the brain
We collected blood and brain tissue for lead analysis from
the cellular cohort at sacrifice after the 12-week lead expos-
ure. Lead exposure significantly raised blood lead levels in
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all animals relative to controls at the end of the 12 week
exposure, and lead levels were higher in exposed
females than males of the same genotype (Fig. 10a).
Lead-exposed animals also had significantly higher
brain lead levels relative to their controls at the end of
the 12-week exposure, with the highest levels in
ApoE4-KI female brains (Fig. 10b). Low-resolution LA-
ICP-MS of sections from a control and a lead-treated
female ApoE4-KI mouse illustrate that adult-only lead
exposure is sufficient to cause increased lead deposition
throughout the brain (Fig. 10c-f ), while levels of the es-
sential metal zinc (an internal control for the imaging
and exposure) were not significantly different between
control and lead-treated mice (data not shown).
Lead decreases proliferation of adult-born cells in the
hippocampus in all lead-exposed mice
Adult hippocampal neurogenesis is the process
whereby adult neural stem cells in the DG of the
hippocampus generate adult-born neurons [31]. These
adult-born neurons can influence hippocampus-
dependent learning and memory [33, 34, 37, 55].
Interestingly, ApoE4 alters adult-born neuron differ-
entiation and maturation in the DG of female ApoE4-
KI mice [40]. Thus, we examined whether adult lead
exposure inhibits adult neurogenesis in the hippocam-
pus and whether there is a GXE between lead expos-
ure and ApoE4 on this process using a second cohort
(the cellular cohort) of mice.
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Fig. 8 Adult lead does not cause significant liver or kidney toxicity or DG volume loss in aged ApoE3-KI and ApoE4-KI mice. 8-week-old female
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To determine if adult-only lead exposure is sufficient
to impair cell proliferation during adult neurogenesis,
we treated half of the cellular cohort of mice with BrdU
2 h prior to sacrifice at the end of the 12-week lead ex-
posure in order to label actively proliferating cells in S-
phase of the cell cycle (Fig. 11). We found that lead sig-
nificantly reduced the total number of BrdU+ cells in all
lead-treated animals compared to their respective con-
trols of the same genotype and sex (Fig. 11a-d). The per-
cent change in BrdU+ cells in lead-treated mice
compared to control mice was not statistically signifi-
cantly different between ApoE3-KI and ApoE4-KI mice,
in either sex (Fig. 11e-f ). These data suggest that adult-
only lead exposure for 12 weeks is sufficient to signifi-
cantly decrease adult-born cell proliferation in the DG
of the hippocampus of all mice. Although this cellular
mechanism does not explain the behavior differences ob-
served between ApoE3-KI vs. ApoE4-KI mice, or be-
tween males and females, it may contribute to the
eventual memory loss in all lead-exposed mice, such as
that observed in the novel object location test.
Lead impairs adult-born neuron differentiation and de-
creases the dendritic complexity of immature neurons in
the DG of female ApoE4-KI mice
We examined the effect of lead on neuronal differenti-
ation of adult-born cells in the DG, using immunostain-
ing for DCX and NeuN as markers of immature and
mature neurons, respectively (Figs. 12a and 13a). BrdU
was administered to the remaining half of the cellular
cohort of mice at 9 weeks into the lead exposure
(3 weeks prior to sacrifice) in order to label 3-week-old
0.2% lead acetate exposure
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adult-born cells. Lead treatment significantly reduced
the proportion of adult-born cells that express DCX
(BrdU+DCX+/total BrdU+) or NeuN (BrdU+NeuN+/total
BrdU+) in female ApoE4-KI mice, but not in other lead-
treated mice (Fig. 12b-c, and Fig. 13b-c), suggesting that
lead inhibits neuronal differentiation of adult-born neu-
rons in the hippocampus and that female ApoE4-KI
mice are more sensitive. There was also a statistically
significant decrease in the number of total adult-born
mature neurons (BrdU+NeuN+) in both male and female
ApoE4-KI mice, although the effect was smaller in males
than in females (Fig. 13d-e).
We also assessed the dendritic morphology, a measure
of neuronal maturation, of adult-born neurons in this
same cohort of mice. Because the acid treatment neces-
sary for BrdU staining damages neuronal processes, we
used DCX immunostaining alone to visualize neuronal
processes of newly generated neurons (Fig. 14a-b, 15a-b).
Neurite tracing and Sholl analysis showed that lead treat-
ment significantly decreased the total dendritic length
(Fig. 14c) and the number of dendritic crossings (Fig. 14e)
in female ApoE4-KI mice. This effect was not seen in
female ApoE3-KI mice (Fig. 14d) or any of the male mice
(Fig. 15). These data suggest that ApoE4-KI females are
more sensitive to the effects of lead on neuronal differenti-
ation and maturation.
Lead reduces the number of GABAergic interneurons in
the DG of ApoE4-KI female mice
GABAergic interneurons play an important role in adult
hippocampal neurogenesis [56]. Previous studies report
that ApoE4-KI female mice exhibit an age-dependent
decrease in the number of GABAergic interneurons in
the DG of the hippocampus, starting at 6 months of age
[12, 14, 40]. Thus, we examined the effect of lead on the
number of GABAergic neurons at the end of the 12-
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week lead exposure (20-weeks old) using GAD67 stain-
ing as a marker (Fig. 16a). There was no significant
difference in the total number of GABAergic neurons
between control ApoE3-KI and ApoE4-KI mice in either
sex (Fig. 16b). However, lead treatment significantly
decreased the number of GAD67+ cells in the DG of
ApoE4-KI females but not in other mice.
Discussion
AD currently affects nearly 35 million people and is pro-
jected to affect 117 million people worldwide by 2050
[57]. AD and cognitive decline are associated with signifi-
cant societal, financial, and health care costs. Yet, there is
a paucity of research on the role of environmental expo-
sures and GXE on neurodegenerative disease risk and AD
pathogenesis. Thus, additional investigation into how
environmental factors and GXE may influence AD risk or
accelerate cognitive decline is of immense public health
importance.
Functional impairment in cognition is often used as a
proxy to estimate the presence and degree of AD-
associated neuropathology [58, 59]. Here, we used
humanized transgenic knock-in mice as an animal model
of human ApoE4 carriers to assess whether there is a
GXE between lead and ApoE4 on cognitive behavior,
and potentially on AD risk. ApoE3-KI and ApoE4-KI
female mice develop spontaneous learning and memory
deficits starting at 15–18 months [12–14]. Consequently,
we assessed learning and memory prior to 15 months of
age to determine if lead can accelerate the onset of cog-
nitive behavior deficits. We defined a GXE as a different
effect of lead exposure on cognitive behavior in mice
expressing the human ApoE4 allele from those express-
ing the human ApoE3 allele. Based on this definition, we
concluded that lead interacts with ApoE4 because we
observed statistically significant deficits in contextual
fear memory and spontaneous alternation in lead-
treated ApoE4-KI female mice but not in other animals.
In addition, lead causes an earlier onset of spatial work-
ing memory deficits in the NOL test in lead-treated
ApoE4-KI mice compared to ApoE3-KI mice, for both
males and females. Together, these data suggest that the
effect of lead exposure on cognitive behavior is different
depending on ApoE genotype. More specifically, a GXE
between lead and ApoE4 may accelerate cognitive
decline, contribute to a more rapid progression from
cognitive aging to mild cognitive impairment, and
potentially contribute to AD. Furthermore, females may
be more susceptible to this GXE.
We found that lead exposure decreased spontaneous al-
ternation in the T-maze in female ApoE4-KI animals.
While alternation is not strictly hippocampus-dependent,
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alternation performance is very sensitive to hippocampal le-
sions [44, 54, 60]. More importantly, impaired alternation
and/or repetitive arm entry has been reported in several dif-
ferent AD-mouse models, including models with presenilin
and amyloid precursor protein mutations [61–64].
Lead exposure also impaired hippocampus-dependent
spatial memory in the NOL test in all lead-treated ani-
mals. Interestingly, lead-exposed ApoE3-KI male mice
developed memory loss in the NOL test at 6 months
post-lead exposure. Moreover, the memory loss in all
lead-exposed animals was persistent through 10 months
post-lead. These data suggest that sub-chronic adult lead
exposure alone is sufficient to cause long lasting or irre-
versible memory impairment, and that this behavior
phenotype can occur long after exposure has ended.
These findings are pertinent to human health because
irreversible loss of memory formation is characteristic of
AD, senile dementia, and up to 50% of Parkinson’s
disease cases [65]. Importantly, the aging population in
the U.S. experienced high lead exposure in early life
[66]. Thus, it is possible that lead exposure may lead to
cognitive impairment later in life and contribute to
cognitive decline associated with aging and neurodegen-
eration, such as late-onset AD.
Epidemiological reports suggest an increased risk of
late-onset AD and increased cognitive decline with mild
cognitive impairment in women [15, 16]. We observed
that lead impaired contextual fear memory and working
memory in the T-maze in female but not male ApoE4-
KI mice. Furthermore, lead-induced spatial memory im-
pairment in the NOL test manifested earlier in females
than males for both ApoE3-KI and ApoE4-KI mice.
These data provide strong evidence for sex differences in
susceptibility to lead-induced cognitive decline in an
animal model and suggest that women may be more
susceptible to cognitive impairment and/or AD following
exposure to toxicants such as lead.
We report average peak blood lead levels of 44.4–
63.4 μg/dL, similar to previous animal studies and compar-
able to some occupational exposure settings in the 20th
century [49, 67–69]. Elevated blood lead levels (≥10 μg/dL
for adults) can still be encountered among U.S. workers,
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and Occupational Safety & Health Administration regula-
tions do not require U.S. workers to be removed from their
job sites until they have a blood lead level ≥ 50 μg/dL. [70].
Importantly, high levels of lead exposure from environmen-
tal sources and in occupational settings are still a major
concern in developing countries [18, 71]. Therefore, 0.2%
lead acetate serves as an experimental model for occupa-
tional exposures globally, for environmental exposure in
developing countries, and for the US population who were
exposed to high levels of environmental lead prior to the
ban of leaded gasoline and paint.
Brain and blood lead levels were highest in female
ApoE4-KI mice. There were no differences in water
consumption during the first week but water consump-
tion thereafter was not monitored. Although we cannot
formally exclude the possibility that ApoE4-KI females
drank more water than other animals after the first week
of lead exposure, there was no statistically significant
difference between blood lead levels of female ApoE3-KI
and ApoE4-KI mice. Thus, it seems unlikely that higher
water consumption alone led to more lead deposition in
the brain of female ApoE4-KI.
It is possible that the ApoE4-KI enhances lead depos-
ition in the brain and differences in brain lead dispos-
ition may contribute to the GXE between ApoE4 and
lead. Interestingly, ApoE4-KI mice exhibit decreased
basement membrane thickness, reduced collagen and
tight junction protein expression, as well as increased
matrix metalloproteinase 9 activity in the blood-brain
barrier, suggesting that more lead may accumulate in the
brain of ApoE4-KI mice due to reduced blood-brain bar-
rier integrity [72–74]. Furthermore, human ApoE4 car-
riers with AD also exhibit a thinner basement
membrane, increased fibrin extravasion, and pericyte
loss in the blood-brain barrier compared to ApoE3-KI
carriers with AD or non-AD controls [75, 76]. Thus, ef-
fects of E4 on the blood-brain barrier may increase the
accumulation of lead in the brain in ApoE4-KI mice or
maybe even in humans, and contribute to more severe
or earlier onset of learning and memory impairments.
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We previously found that lead can impair the survival,
proliferation, and differentiation of adult neural precursor
cells in vitro [41]. Thus, we sought to determine whether
lead can interact with ApoE4 to impair adult hippocampal
neurogenesis in vivo and whether this could be an under-
lying mechanism for the observed cognitive deficits. We
exposed mice to lead starting at 8 weeks of age in order to
avoid the cumulative effects of lead on both the develop-
ing and adult brain [77]. Unlike previous reports using the
ApoE3-KI and ApoE4-KI models, we did not see a signifi-
cant effect of ApoE4 alone on adult-born cell proliferation
and maturation. This may be due to the fact that the
effects of ApoE4 are age-dependent and we analyzed adult
neurogenesis 1.5–2.5 months earlier (in 4.6-month-old vs.
6–7-month-old mice) than previous studies [12, 14, 40].
Data presented here demonstrate that adult lead exposure
impairs adult-born cell proliferation in all lead-treated ani-
mals; this mechanism may contribute to lead impairment
of spatial memory in the novel object location test that
eventually develop in all lead-treated mice. Furthermore,
lead exposure significantly impaired adult-born neuron
differentiation and decreased dendritic complexity spe-
cifically in ApoE4-KI females. These cellular changes
correlate with the fact that lead impairment of cogni-
tion is most pronounced in ApoE4-KI females. There
was also a statistically significant reduction in the num-
ber of adult-born mature neurons (BrdU+NeuN+ cells)
in male ApoE4-KI mice, although the reduction is
smaller than that in females. This cellular change oc-
curs at the end of the 12-week lead exposure and
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correlates with the onset of NOL deficits in the lead-
treated ApoE4-KI males in the behavior cohort. To-
gether, these data suggest that lead and ApoE4 may
interact to perturb neuronal differentiation and matur-
ation during adult hippocampal neurogenesis, and that
this mechanism may contribute to the lead and ApoE4
interaction on accelerated cognitive impairment in
ApoE4 mice and the heightened sensitivity of ApoE4
females.
The survival and integration of adult-born neurons is
activity-dependent and occurs at approximately three
weeks after neuronal birth [78, 79]. Several different cell
types and inputs facilitate the survival and maturation of
adult-born cells during this window, including GABAergic
interneurons that may exert trophic effects on adult-born
immature neuron survival and maturation [56, 80, 81].
Previous studies found that there are basal sex differences
in the number of GAD67+ interneurons in ApoE3-KI and
ApoE4-KI mice, with female mice having significantly
more GAD67+ interneurons, and that female ApoE4-KI
mice have significantly fewer GAD67+ cells than ApoE3-
KI mice starting at 6–7 months of age [40]. We found that
lead significantly decreased the total number of GAD67+
cells in 20-week-old, lead-treated ApoE4-KI females. This
cellular effect correlates closely with our observation of
significantly reduced adult-born neuron maturation and
dendritic complexity in ApoE4-KI females, suggesting that
an interaction between lead and ApoE4 may contribute to
earlier impairment of GABAergic input and contribute to
the observed impairment in immature neuron maturation
in ApoE4-KI females.
Adult-born, immature neurons play a critical role in
synaptic plasticity within the DG [79, 82, 83]. Notably,
the increased responsiveness and excitability of newborn
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granule cells may give these adult-born cells a specific
and significant role in learning and memory [55, 84]. In
rats, a greater proportion of young, adult-born neurons
are activated during spatial exploration compared to
existing granule cells [85, 86]. Similarly, the selective loss
of immature neurons impairs long-term spatial memory
retention and contextual fear extinction [36]. Thus, the
disruption of adult-born immature neuron maturation in
lead-treated ApoE4-KI females may be associated with
the impaired hippocampus-dependent learning and
memory in these mice.
Although lead was deposited in the mouse brain broadly
including the hippocampus and no regional specific
deposition was found, we did not observe overt motor
impairment. In humans, high levels of lead exposure can
cause fine and gross motor impairments. However, lead
exposure during development, which interferes with the
proper development of the nervous system, likely plays a
significant role in these cases. In the present study, mice
were exposed to lead beginning at 8 weeks of age, elimin-
ating the effect of lead on the developing nervous system.
We only measured gross motor function (open field test),
so we cannot rule out if lead exposure caused fine motor
dysfunction. We did not observe a significant increase in
TUNEL+ cells in the hippocampus or cortex of lead-
treated animals. However, lead impaired adult neurogen-
esis in the hippocampus, with the greatest effect seen in
female ApoE4-KI mice. Thus, newborn cells and neurons
in the hippocampus, especially those in mice expressing
human ApoE4 allele, may be more vulnerable than
neurons in other regions of the brain to lead toxicity in
the adult mice.
Similar to other studies that have reported basal sex
differences in adult neurogenesis in these mice [14], we
report baseline differences in the total number of adult-
born cells (total BrdU+ cells), and the total number of
GAD67+ cells in the DG between control males and
females. However, we do not think these differences alter
the conclusions of this study. For example, we found
that all control mice performed equally well in tests for
contextual fear memory, spontaneous alternation in the
T-maze, and memory for novel object location (NOL).
In addition, while ApoE3-KI and ApoE4-KI male mice
had a lower number of BrdU+ and GAD67+ cells, they
did not show statistically significant memory deficits
after lead exposure when tested for contextual fear
a
b
Fig. 16 Lead decreases the total number of GAD67+ GABAergic interneurons in 20-week-old female ApoE4-KI mice. 8-week-old male and female
ApoE3-KI and ApoE4-KI mice were exposed to 0.2% lead acetate for 12 weeks and sacrificed. a Representative images of GAD67 (red) immunostaining
in the DG of 20-week-old female ApoE3-KI and ApoE4-KI control and lead-treated mice. b Quantification of the total number of GAD67+ cells in the
DG of 20-week-old ApoE3-KI and ApoE4-KI females and males. Data are mean ± SEM with n = 3–5 per genotype/treatment. Two-way ANOVA with
Fisher’s LSD post-test. Comparison between control and lead-treated: n.s., not significant; * p < 0.05. Comparison between males and females of the
same genotype and treatment: n.s., not significant; #, p < 0.05; ##, p < 0.01. Scale bars, 100 μm
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memory or spontaneous alternation in the T-maze. They
also exhibited a later onset of deficits in the NOL test
than their respective females of the same genotype.
These data suggest that the lower basal adult neurogen-
esis in males does not affect their basal shot-term spatial
and contextual memory, nor lead to higher sensitivity to
lead impairment of cognition.
Conclusions
Although it has been hypothesized that exposure to envir-
onmental factors and a GXE interaction may increase AD
risk, there is little direct evidence supporting this hypoth-
esis. In this study, we found that adult lead exposure is
sufficient to impair hippocampus-dependent learning and
memory and that these deficits are more severe or occur
earlier in female ApoE4-KI mice. These findings provide
some of the first direct evidence for a GXE interaction
between lead and ApoE4 on cognitive impairment.
Furthermore, impaired adult hippocampal neurogenesis
may be a potential mechanism underlying this GXE inter-
action. These results also provide new insight into how
environmental toxicants and genetic risk factors may
interact to contribute to cognitive decline and neurode-
generation in non-AD patients.
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